Sangamo Biosciences (SGMO) 14.70 $SGMO
Sangamo BioSciences ups revenues 67% in Q1
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:15AM CDT
SGMO: 14.70 (-0.84)
Sangamo Biosciences' (SGMO) CEO Edward Lanphier on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 8:47PM CDT
SGMO: 14.70 (-0.84)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:35PM CDT
OII: 54.10 (-1.47), EBAY: 59.20 (+0.31), CAKE: 52.98 (+0.56), ARRS: 35.76 (-1.54), XLNX: 42.88 (-0.88), AFOP: 19.33 (-0.43), TXN: 54.73 (+0.01), SGMO: 14.70 (-0.84), MOBL: 6.97 (-0.14), LVS: 55.25 (+0.13)
Sangamo BioSciences (SGMO) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Apr 22, 3:55PM CDT
SGMO: 14.70 (-0.84)
Sangamo BioSciences beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:05PM CDT
SGMO: 14.70 (-0.84)
Sangamo BioSciences Reports First Quarter 2015 Financial Results
PR Newswire - Wed Apr 22, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments.
SGMO: 14.70 (-0.84)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:35PM CDT
SKX: 89.66 (+2.79), SLG: 128.82 (+1.47), AMP: 127.75 (+0.58), CTXS: 66.99 (-0.35), WSTC: 32.20 (-0.01), SLM: 10.25 (+0.02), CAKE: 52.98 (+0.56), WFT: 14.16 (-0.05), TYL: 132.12 (+1.82), FFIV: 123.18 (+0.78), LOGI: 15.01 (-0.47), MKSI: 35.94 (+0.44), FTK: 14.06 (-0.43), AHL: 47.77 (-0.09), TMK: 56.09 (-0.11), HNI: 51.98 (+0.71), FOE: 12.62 (unch), FB: 81.53 (-0.88), PLCM: 12.94 (-0.15), CLB: 124.69 (-0.63), XLNX: 42.88 (-0.88), RJF: 57.06 (-0.50), TXN: 54.73 (+0.01), AF: 13.05 (-0.06), VMI: 124.44 (+1.30), CCI: 85.98 (-0.66), OII: 54.10 (-1.47), CLW: 64.38 (+0.21), AFOP: 19.33 (-0.43), SGMO: 14.70 (-0.84), LVS: 55.25 (+0.13), AWH: 41.69 (-0.02), TSCO: 90.98 (-0.28), USTR: 42.07 (-0.28), CVA: 20.97 (-0.40), T: 34.01 (-0.22), EBAY: 59.20 (+0.31), IBKC: 62.86 (-0.61), CNMD: 53.40 (-0.83), QCOM: 68.24 (-0.10), PLXS: 44.20 (-0.32), BDN: 15.00 (+0.35), SUSQ: 13.40 (-0.01), NEU: 461.52 (-7.91), GGG: 71.11 (-1.09), ORLY: 229.35 (+1.04), CYS: 9.15 (+0.05), LHO: 38.40 (-0.10), EFX: 98.49 (+0.09), CUB: 50.07 (-0.15), ALGT: 168.12 (+1.10), TCBI: 51.61 (-0.61), SCSS: 34.50 (+0.86), CLGX: 39.45 (+0.23), IGT: 20.21 (+0.21)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
Sangamo BioSciences Announces First Quarter 2015 Conference Call and Webcast
PR Newswire - Wed Apr 15, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its first quarter 2015 financial results after the market closes on Wednesday, April 22, 2015. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 14.70 (-0.84)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology
SYN: 2.33 (+0.01), AMRS: 2.52 (-0.09), A: 42.49 (-0.13), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), GEVO: 2.72 (-0.10), SZYM: 3.79 (-0.11)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), SNHY: 41.42 (+0.11), EBIX: 29.77 (-0.21), SWHC: 15.01 (+0.10)
3 Biotechs That Could Change Medicine Forever: Wasatch Analyst Jill Wahleithner
Life Sciences Report - Seeking Alpha - Thu Mar 26, 5:01PM CDT
Buyside analysts don't publish ratings and target prices for the public: Nearly all their notes, analyses and projections are top secret. However, in this interview with The Life Sciences Report , Wasatch Advisors' Jill Wahleithner breaks that...
INO: 10.35 (-0.25), ARGS: 8.56 (-0.18), SGMO: 14.70 (-0.84)
Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 24.18 (-0.25), ARWR: 7.28 (+0.05), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), KMDA: 4.71 (-0.01), IBIO: 1.07 (+0.07)
19.1% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Mon Mar 23, 9:27AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on February 12th, 2015 at $14.59. In approximately 1 month, Sangamo Biosciences has returned 19.12% as of today's recent price of $17.38.
SGMO: 14.70 (-0.84)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 131.01 (-1.50), SGMO: 14.70 (-0.84), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26), EXEL: 3.08 (-0.02)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 136.26 (-3.82), QURE: 26.09 (-0.28), SGMO: 14.70 (-0.84), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), NVS: 104.28 (-1.22)
Sangamo BioSciences Announces Participation In The 3rd Annual Regen Med Investor Day Meeting In New York
PR Newswire - Wed Mar 18, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 1:55pm ET on Wednesday, March 25, 2015, at the 3rd Annual Regen Med Investor Day. The meeting will be held in New York City.
SGMO: 14.70 (-0.84)
Sangamo Biosciences Has Returned 19.3% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Fri Mar 13, 5:05PM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on February 12th, 2015 at $14.59. In approximately 4 weeks, Sangamo Biosciences has returned 19.26% as of today's recent price of $17.40.
SGMO: 14.70 (-0.84)
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia
Alpha Exposure - Seeking Alpha - Mon Mar 09, 3:20PM CDT
Sangamo Biosciences (NASDAQ: SGMO ) was founded in 1995 1 ostensibly to commercialize zinc finger nuclease technology. Twenty years have passed since its founding and there hasn't been a single drug approval nor is one imminent. In twenty years,...
BLUE: 136.26 (-3.82), SGMO: 14.70 (-0.84)
Sangamo BioSciences ups revenues 67% in Q1
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:15AM CDT
SGMO: 14.70 (-0.84)
Sangamo Biosciences' (SGMO) CEO Edward Lanphier on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 8:47PM CDT
SGMO: 14.70 (-0.84)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:35PM CDT
OII: 54.10 (-1.47), EBAY: 59.20 (+0.31), CAKE: 52.98 (+0.56), ARRS: 35.76 (-1.54), XLNX: 42.88 (-0.88), AFOP: 19.33 (-0.43), TXN: 54.73 (+0.01), SGMO: 14.70 (-0.84), MOBL: 6.97 (-0.14), LVS: 55.25 (+0.13)
Sangamo BioSciences (SGMO) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Apr 22, 3:55PM CDT
SGMO: 14.70 (-0.84)
Sangamo BioSciences beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:05PM CDT
SGMO: 14.70 (-0.84)
Sangamo BioSciences Reports First Quarter 2015 Financial Results
PR Newswire - Wed Apr 22, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments.
SGMO: 14.70 (-0.84)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:35PM CDT
SKX: 89.66 (+2.79), SLG: 128.82 (+1.47), AMP: 127.75 (+0.58), CTXS: 66.99 (-0.35), WSTC: 32.20 (-0.01), SLM: 10.25 (+0.02), CAKE: 52.98 (+0.56), WFT: 14.16 (-0.05), TYL: 132.12 (+1.82), FFIV: 123.18 (+0.78), LOGI: 15.01 (-0.47), MKSI: 35.94 (+0.44), FTK: 14.06 (-0.43), AHL: 47.77 (-0.09), TMK: 56.09 (-0.11), HNI: 51.98 (+0.71), FOE: 12.62 (unch), FB: 81.53 (-0.88), PLCM: 12.94 (-0.15), CLB: 124.69 (-0.63), XLNX: 42.88 (-0.88), RJF: 57.06 (-0.50), TXN: 54.73 (+0.01), AF: 13.05 (-0.06), VMI: 124.44 (+1.30), CCI: 85.98 (-0.66), OII: 54.10 (-1.47), CLW: 64.38 (+0.21), AFOP: 19.33 (-0.43), SGMO: 14.70 (-0.84), LVS: 55.25 (+0.13), AWH: 41.69 (-0.02), TSCO: 90.98 (-0.28), USTR: 42.07 (-0.28), CVA: 20.97 (-0.40), T: 34.01 (-0.22), EBAY: 59.20 (+0.31), IBKC: 62.86 (-0.61), CNMD: 53.40 (-0.83), QCOM: 68.24 (-0.10), PLXS: 44.20 (-0.32), BDN: 15.00 (+0.35), SUSQ: 13.40 (-0.01), NEU: 461.52 (-7.91), GGG: 71.11 (-1.09), ORLY: 229.35 (+1.04), CYS: 9.15 (+0.05), LHO: 38.40 (-0.10), EFX: 98.49 (+0.09), CUB: 50.07 (-0.15), ALGT: 168.12 (+1.10), TCBI: 51.61 (-0.61), SCSS: 34.50 (+0.86), CLGX: 39.45 (+0.23), IGT: 20.21 (+0.21)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
Sangamo BioSciences Announces First Quarter 2015 Conference Call and Webcast
PR Newswire - Wed Apr 15, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the company will release its first quarter 2015 financial results after the market closes on Wednesday, April 22, 2015. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss other business matters.
SGMO: 14.70 (-0.84)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology SYN: 2.33 (+0.01), AMRS: 2.52 (-0.09), A: 42.49 (-0.13), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), GEVO: 2.72 (-0.10), SZYM: 3.79 (-0.11)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), AFFX: 12.44 (-0.16), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), EXAM: 43.13 (-0.04), IART: 61.31 (+0.84), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), CTRN: 24.69 (+0.29), ANAC: 64.49 (-2.10), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), FARO: 43.44 (-1.22), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), SNHY: 41.42 (+0.11), EBIX: 29.77 (-0.21), SWHC: 15.01 (+0.10)
3 Biotechs That Could Change Medicine Forever: Wasatch Analyst Jill Wahleithner
Life Sciences Report - Seeking Alpha - Thu Mar 26, 5:01PM CDT
Buyside analysts don't publish ratings and target prices for the public: Nearly all their notes, analyses and projections are top secret. However, in this interview with The Life Sciences Report , Wasatch Advisors' Jill Wahleithner breaks that...
INO: 10.35 (-0.25), ARGS: 8.56 (-0.18), SGMO: 14.70 (-0.84)
Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 24.18 (-0.25), ARWR: 7.28 (+0.05), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), KMDA: 4.71 (-0.01), IBIO: 1.07 (+0.07)
19.1% Return Seen to Date on SmarTrend Sangamo Biosciences Call (SGMO)
Comtex SmarTrend(R) - Mon Mar 23, 9:27AM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on February 12th, 2015 at $14.59. In approximately 1 month, Sangamo Biosciences has returned 19.12% as of today's recent price of $17.38.
SGMO: 14.70 (-0.84)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 29.91 (-0.42), PMC: 30.50 (-0.29), MATW: 50.80 (-0.20), ELLI: 57.75 (+0.69), WWE: 14.48 (-0.18), SILC: 44.20 (+1.71), SGMO: 14.70 (-0.84), TRNX: 26.25 (+0.01), OFIX: 36.46 (+0.10), AFFX: 12.44 (-0.16), CHE: 123.62 (+0.08), BABY: 42.15 (-0.01), HBIO: 6.22 (+0.08), IART: 61.31 (+0.84), SONC: 30.83 (-0.21), SNCR: 51.48 (-0.44), CNMD: 53.40 (-0.83), BJRI: 49.52 (-3.92), NLNK: 52.10 (-0.90), ANAC: 64.49 (-2.10), XSD: 85.14 (-2.91), PRSC: 49.35 (+0.02), RRGB: 83.32 (+1.41), IPAR: 31.75 (-0.88), ALOG: 88.06 (-0.13), DIOD: 27.28 (-0.72), NSIT: 28.68 (+0.01), LGND: 89.75 (+0.83), DEPO: 27.65 (+0.36), ASTE: 43.09 (+0.01), DYAX: 27.44 (-0.85), ECOL: 49.43 (+0.31), PFPT: 54.33 (-2.60), MTSI: 31.41 (-1.92), IRWD: 15.10 (-0.38), ABAX: 63.62 (+0.31), FLDM: 42.47 (-0.73), SCSS: 34.50 (+0.86), ANIP: 70.26 (-1.52), FORM: 9.16 (-0.13), BEAT: 8.60 (-0.26), QLGC: 15.26 (+0.07), ADUS: 28.86 (+0.41), PENX: 18.98 (+0.14), EBIX: 29.77 (-0.21), CORT: 6.32 (-0.12), SWHC: 15.01 (+0.10), OCFC: 17.32 (+0.42)
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 131.01 (-1.50), SGMO: 14.70 (-0.84), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26), EXEL: 3.08 (-0.02)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 136.26 (-3.82), QURE: 26.09 (-0.28), SGMO: 14.70 (-0.84), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), NVS: 104.28 (-1.22)
Sangamo BioSciences Announces Participation In The 3rd Annual Regen Med Investor Day Meeting In New York
PR Newswire - Wed Mar 18, 3:02PM CDT
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 1:55pm ET on Wednesday, March 25, 2015, at the 3rd Annual Regen Med Investor Day. The meeting will be held in New York City.
SGMO: 14.70 (-0.84)
Sangamo Biosciences Has Returned 19.3% Since SmarTrend Recommendation (SGMO)
Comtex SmarTrend(R) - Fri Mar 13, 5:05PM CDT
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on February 12th, 2015 at $14.59. In approximately 4 weeks, Sangamo Biosciences has returned 19.26% as of today's recent price of $17.40.
SGMO: 14.70 (-0.84)
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia
Alpha Exposure - Seeking Alpha - Mon Mar 09, 3:20PM CDT
Sangamo Biosciences (NASDAQ: SGMO ) was founded in 1995 1 ostensibly to commercialize zinc finger nuclease technology. Twenty years have passed since its founding and there hasn't been a single drug approval nor is one imminent. In twenty years,...
BLUE: 136.26 (-3.82), SGMO: 14.70 (-0.84)
